yeah i can see it drop a bit but it will hold in the 4s and it can take its time to get to the 5s lol, id like to get in some more, got in at under a dollar and just over a dollar, so yeah, moon is looking pretty damn good! GD luck to all.
Sentiment: Strong Buy
Of Our Minds. He Pointed Out The House He Grew Up In, But Being As He Was Older Than Me I Didn't Remember Him. I Grew Up In The Same Neighborhood. We Were Talking A Little Politics Eventually & I Remember Concluding That He Was Selling god. So I Told Him I Was Thinking Of Buying Some god & I Wanted To Know How Much It Would Cost Me.
While MannKind's hopes are pinned on Afrezza, the company does have more products in its pipeline. One is its MKC1106 cancer immunotherapy drug. The drug showed promise in early-stage testing and advanced to a phase 2 study.
However, MannKind doesn't have room from a resource standpoint to handle anything other than Afrezza. The company halted development on most other programs to focus primarily on its inhalable insulin program. That's where the garage sale comes into play.
MannKind announced on Nov. 13 that it inked a deal with privately held Colby Pharmaceutical. Colby will gain exclusive global rights to MKC1106. In return, MannKind will receive an upfront payment and potential milestone payments that could total $140 million. MannKind will also receive tiered royalties if MKC1106 makes its way to market.
This isn't the first item to be sold from the garage. In April, MannKind announced an agreement to license its Bruton's tyrosine kinase program to Tolero Pharmaceuticals. That arrangement could ultimately generate up to $130 million in upfront and milestone payments.
The potential exists for more deals. MannKind thinks that its Technosphere technology could be used to more effectively deliver other drugs that currently require injections.
who knows. Maybe they have an acquisition & promotion and need the cash. They mention it in every presentation.
To do a share offering like this without news just before an institutional CC I think is suicidal.
Let's see what happens.
Historically they raise capital about $15M. If this time is the same, I think the price will be around 25M shares at $0.6.
And now obamacare to be stricken by SUPREME COURT.
Bought in at 13 back in 2012, was hoping Skul would have been the target for Apple but they went for Beat instead. I hope this is real. Would like to return a small profit on this as I still feel it was an investment in a fundamentally good company- pity there was so much short pressure that has limited the companies growth made it look like a tech bubble IPO
The NTA is 726.91m i.e. after deducting the liabilities. Even if the assets are reduced by 100m , it is still over 600m.